Business Standard

Intas launches immuno-booster add-on drug to standard Covid-19 treatment

The formulation is the active biological component of black cumin; it fortifies the immunity and ensures higher success in fighting infection, the company says

Intas Pharmaceuticals
Premium

The drug's anti-viral effects have been demonstrated via an in-vitro test against SARS-CoV2. Photo is representational.

Vinay Umarji Ahmedabad
In its bid to provide an add-on to standard Covid-19 treatment, drug maker Intas has launched a novel, patented research formulation of Thymoquinone under the brand name of Thymotas that fortifies immunity and ensures higher success in fighting infection. 

Tested clinically, the Thymotas 12.5 mg is successful in building immunity and combating infections effectively in the current pandemic, the company stated on Tuesday. According to Intas, Thymotas' anti-viral effects have been demonstrated via an in-vitro test against SARS-CoV2 and has tremendous potential as a potent add-on to the standard treatment in COVID-19.

Thymoquinone is the active biological component of Nigella sativa, also

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in